An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

[1]  H. Einsele,et al.  ASTCT Clinical Practice recommendations for transplant and cellular therapies in multiple myeloma. , 2022, Transplantation and cellular therapy.

[2]  P. Sonneveld,et al.  Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment , 2022, Frontiers in Oncology.

[3]  Shaji K. Kumar,et al.  Post-Transplant Maintenance Treatment Options in Multiple Myeloma , 2021, Oncology and Therapy.

[4]  H. Goldschmidt,et al.  Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  P. Hari,et al.  Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma , 2020, British journal of haematology.

[6]  G. Morgan,et al.  Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma , 2020, British journal of haematology.

[7]  M. Dimopoulos,et al.  Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. , 2020, Clinical lymphoma, myeloma & leukemia.

[8]  M. Mohty,et al.  Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk , 2019, Haematologica.

[9]  W. Wiktor-Jedrzejczak,et al.  Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party , 2017, Haematologica.

[10]  D. Dingli,et al.  Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  J. Crowley,et al.  Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma , 2016, Blood Cancer Journal.

[12]  E. Steyerberg,et al.  [Regression modeling strategies]. , 2011, Revista espanola de cardiologia.

[13]  D. Dingli,et al.  Impact of early relapse after auto-SCT for multiple myeloma , 2008, Bone Marrow Transplantation.